Comparing two methods for oocyte collection in women with low ovarian reserve
Dydrogesterone Primed Ovarian Stimulation Versus Fixed Gonadotropin Releasing Hormone Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: A Randomized Controlled Trial
This study is testing two different methods for collecting eggs in women with low ovarian reserve to see which one helps gather more usable eggs for future fertility treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 730 (estimated) |
| Ages | 18 Years to 37 Years |
| Sex | Female |
| Sponsor | Tam Anh TP. Ho Chi Minh General Hospital Academic / other |
| Locations | 2 sites (Hanoi, Hanoi and 1 other locations) |
| Trial ID | NCT05847283 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effectiveness of a Dydrogesterone-primed ovarian stimulation (DPOS) protocol against a GnRH antagonist protocol for oocyte accumulation in women with diminished ovarian reserve. Eligible participants, aged 18 to 37 with low ovarian reserve indicators, will be randomly assigned to one of the two treatment groups. Both groups will undergo a standardized ovarian stimulation regimen, followed by oocyte retrieval and cryopreservation. The study is designed to assess which protocol yields a higher number of viable oocytes for future use in assisted reproductive technology.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 to 37 with an antral follicle count of 5 or less and/or an AMH level of 1.2 ng/ml or lower.
Not a fit: Patients who are oocyte recipients, have contraindications to ART, or have a history of repeated implantation failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective and patient-friendly approach to oocyte collection for women with diminished ovarian reserve.
How similar studies have performed: While there have been various ovarian stimulation protocols, the specific comparison of DPOS versus GnRH antagonist in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Woman aged between 18 and 37 years * AFC ≤ 5 and/or AMH ≤ 1.2 ng/ml * Agree to perform freeze-all strategy and single frozen blastocyst embryo transfer Exclusion Criteria: * Oocyte recipient * Indication of preimplantation genetic testing * Known allergic reactions to medications in the Study (progesterone products, GnRH antagonist….) * Basal FSH above 15mIU/mL. * Have contraindications of ART treatment (e.g. critical or acute diseases) * Retrieved sperm * Repeated Implantation failure ( ≥ 3 failed embryo transfers with good-quality embryos) * Inability to comply with the study procedures. * Patients with a history of thyroid cancer who are on hormone replacement therapy or those diagnosed with thyroid diseases at the time of eligibility assessment
Where this trial is running
Hanoi, Hanoi and 1 other locations
- Ivfta — Hanoi, Hanoi, Vietnam (Recruiting)
- Ivfta Hcmc — Ho Chi Minh City, Ho Chi Minh, Vietnam (Recruiting)
Study contacts
- Principal investigator: Nhu H Giang, MD., MCE — Tam Anh TP. Ho Chi Minh General Hospital
- Study coordinator: Nhu H Giang, MD., MCE
- Email: nhugh@tahospital.vn
- Phone: +84 793 231 721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.